Edward B. Garon MD, MS, engaged in a stimulating debate regarding the relevancy of angioinhibition in the management of NSCLC, particularly for EGFR-positive patients, at the virtual 2020…
At the virtual 2020 Personalized Therapies in Thoracic Oncology meeting, Jonathan Goldman, MD, provided an overview of how to manage patients with ALK-resistance in non-small-cell lung cancer (NSCLC).
In a session presented at the 2020 Personalized Therapies in Thoracic Oncology virtual meeting, Alexander Drilon PhD, Memorial Sloan Kettering Cancer Center, New York, shared insight on MET-dependent…
Dr Lisberg discusses when to use checkpoint inhibitor therapy for targetable mutations in NSCLC, a recap of his presentation at the 2020 Personalized Therapies in Thoracic Oncology meeting.
In the second installment of this roundtable discussion, experts sat down with Oncology Learning Network to discuss use of liquid biopsies to detect treatment resistance in lung cancer, areas for…
Joshua Bauml, MD, Lyudamila Bazhenova, MD, Jarushka Naidoo, M.B.B.Ch, discuss evolution and utilization of liquid biopsies in NSCLC in part 1 of this virtual roundtable discussion.
In a session presented at the 2020 Personalized Therapies in Thoracic Oncology virtual meeting, Stephen V. Liu, MD, Georgetown Lombardi Comprehensive Cancer Center, Washington, D.C, shared insight on…
At the virtual 2020 Personalized Therapies in Thoracic Oncology meeting, Gregory J. Riely, MD, PhD, provided an overview of the current front-line therapies for patients with EGFR+ lung cancer.
Stay in the know.
OncNet Newsletter